Mesource Pharmaceuticals

Mesource Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics, particularly in the field of nuclear receptor modulation. The company leverages its expertise in medicinal chemistry and structural biology to target endocrine-related diseases and oncology, with a specific emphasis on hormone-dependent cancers such as breast and prostate cancer. Mesource aims to develop next-generation treatments that overcome resistance to current endocrine therapies. While currently in the early stages of development, the company is building a pipeline of selective modulators designed to improve patient outcomes in metabolic and oncological indications.